Why Inicure
A different route to treating infection.
By developing novel anti-infective compounds that work through the innate immune system, Inicure is addressing a global health threat and a substantial, growing market.
$10M
Inicure's adressable market
Host-directed, not bacteria-directed
The compounds work through the innate immune system rather than attacking bacteria, significantly lowering the risk of resistance development.
A new mechanism of action
Selective FPR1 agonism driving NOX2-produced ROS is a fundamentally new approach to inhibiting and treating infection and inflammation.
Topical to systemic versatility
Water-solubility and specificity allow applications from infected wounds to severe systemic infections such as urinary tract infections.
Patent-protected assets
Inicure is developing patent-protected compounds, supported by peer-reviewed science and an experienced drug development team.
Support and recognition
- EIC Seal of Excellence
- EIC Booster grant
- INCATE support
- GU Ventures
- Västra Götalandsregionen
- Potter Clarkson